Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor Adds Claims For High-Dose Use From TNT, IDEAL – But Label Is Mixed

Executive Summary

Lipitor (atorvastatin) has gained approval for five new indications based on the Treating to New Targets and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering studies, but the updated labeling includes mixed statements about the benefits of treatment with higher doses of atorvastatin

You may also be interested in...



ACCORD Trial Complicates “Treating To New Targets” Theory In Diabetes

The large government-sponsored ACCORD trial in type 2 diabetes has stumbled in trying to show that driving down blood glucose to normal levels can improve cardiovascular outcomes in high-risk patients

ACCORD Trial Complicates “Treating To New Targets” Theory In Diabetes

The large government-sponsored ACCORD trial in type 2 diabetes has stumbled in trying to show that driving down blood glucose to normal levels can improve cardiovascular outcomes in high-risk patients

After Early Blow, Pfizer Prepares For Round Two Of Lipitor/Generic Zocor Fight

Although Lipitor has taken a beating in the run up to the launch of generics of Merck's Zocor, Pfizer is gearing up for a second round of movement in the cholesterol market, during which patients inadequately controlled on generic statins will switch to Lipitor, Pfizer CEO Hank McKinnell said June 13

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel